Thymic involution and corticosterone level in Sandhoff disease model mice: new aspects the pathogenesis of GM2 gangliosidosis
- 198 Downloads
Sandhoff disease (SD) is a lysosomal disease caused by a mutation of the HEXB gene associated with excessive accumulation of GM2 ganglioside (GM2) in lysosomes and neurological manifestations. Production of autoantibodies against the accumulated gangliosides has been reported to be involved in the progressive pathogenesis of GM2 gangliosidosis, although the underlying mechanism has not been fully elucidated. The thymus is the key organ in the acquired immune system including the development of autoantibodies. We showed here that thymic involution and an increase in cell death in the organ occur in SD model mice at a late stage of the pathogenesis. Dramatic increases in the populations of Annexin-V+ cells and terminal deoxynucletidyl transferase dUTP nick end labeling (TUNEL) + cells were observed throughout the thymuses of 15-week old SD mice. Enhanced caspase-3/7 activation, but not that of caspase-1/4, -6 ,-8, or −9, was also demonstrated. Furthermore, the serum level of corticosterone, a potent inducer of apoptosis of thymocytes, was elevated during the same period of apoptosis. Our studies suggested that an increase in endocrine corticosterone may be one of the causes that accelerate the apoptosis of thymocytes leading to thymic involution in GM2 gangliosidosis, and thus can be used as a disease marker for evaluation of the thymic condition and disease progression.
KeywordsCorticosterone Enzyme Replacement Therapy Thymic Involution Gangliosidosis Thymus Weight
This work was supported by the Program the Promotion of Fundamental Studied Health Sciences of the National Institute of Biomedical Innovation (NIBIO) (Osaka, Japan), and a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
- Boot RG, Verhoek M, Fost ND et al. (2004) Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate maker for assessing therapeutic intervention. Blood 103:33–39Google Scholar
- Gravel A, Kaback M, Proia RL et al. (2001) The GM2 gangliosidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited diseases, 8th edn. McGraw-Hill, New York, pp 3827–3877Google Scholar
- Wu YY, Locker JM, Sugiyama E et al. (1994) Expression and specificity of human GM2 activator protein. J Biol Chem 269:6276–6283Google Scholar